These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 8932813

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
    Schmitz N, Dreger P, Zander AR, Ehninger G, Wandt H, Fauser AA, Kolb HJ, Zumsprekel A, Martin A, Hecht T.
    Bone Marrow Transplant; 1995 Feb; 15(2):261-6. PubMed ID: 7539668
    [Abstract] [Full Text] [Related]

  • 3. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia.
    Locatelli F, Pession A, Zecca M, Bonetti F, Prete L, Carrà AM, Prete A, Montagna D, Comoli P, Taibi RM, Paolucci G.
    Bone Marrow Transplant; 1996 Jan; 17(1):31-7. PubMed ID: 8673051
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH, Schulman KA, Buckner CD.
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [Abstract] [Full Text] [Related]

  • 6. Effect of peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.
    Grigg A, Begley CG, Juttner CA, Szer J, To LB, Maher D, McGrath KM, Morstyn G, Fox RM, Sheridan WP.
    Bone Marrow Transplant; 1993 May; 11 Suppl 2():23-9. PubMed ID: 8334435
    [Abstract] [Full Text] [Related]

  • 7. G-CSF after autologous bone marrow transplantation for malignant diseases in children. Spanish Working Party for Bone Marrow Transplantation in Children.
    Madero L, Muõnz A, Diaz de Heredia A, Martínez A, Badell I, Esquembre C, Ramírez M, Otheo E, Olive A, Sastre A.
    Bone Marrow Transplant; 1995 Mar; 15(3):349-51. PubMed ID: 7541268
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy.
    Kim IH, Park SK, Suh OK, Oh JM.
    Curr Med Res Opin; 2003 Mar; 19(8):753-9. PubMed ID: 14687447
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT, Krog C, Stockschläder M, Schleimer B, Zeller W, Krüger W, Erttmann R, Zander AR.
    Anticancer Res; 1997 Mar; 17(1B):589-99. PubMed ID: 9066585
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
    Meisel R, Enczmann J, Balzer S, Bernbeck B, Kramm C, Schönberger S, Sinha K, Tröger A, Wernet P, Göbel U, Laws HJ, Dilloo D.
    Klin Padiatr; 2005 Mar; 217(3):135-41. PubMed ID: 15858704
    [Abstract] [Full Text] [Related]

  • 17. Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies.
    Vicent MG, Madero L, Chamorro L, Madero R, Diaz MA.
    Haematologica; 2001 Oct; 86(10):1087-94. PubMed ID: 11602415
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Late G-CSF after allogeneic bone marrow or peripheral blood stem cell transplantation: a prospective controlled trial.
    Himmelmann B, Himmelmann A, Furrer K, Halter J, Schanz U.
    Bone Marrow Transplant; 2002 Oct; 30(8):491-6. PubMed ID: 12379887
    [Abstract] [Full Text] [Related]

  • 20. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.
    Bolwell B, Vredenburgh J, Overmoyer B, Gilbert C, Chap L, Menchaca DM, Cruickshank S, Glaspy J.
    Bone Marrow Transplant; 2000 Jul; 26(2):141-5. PubMed ID: 10918423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.